In this study, we aimed to evaluate whether the novel pretreatment Global Immune-Nutrition-Inflammation Index (GINI) can predict radiation-induced trismus (RIT) in locally advanced nasopharyngeal carcinoma (LA-NPC) patients undergoing concurrent chemoradiotherapy (CCRT). Data of LA-NPC patients presenting without RIT were reviewed retrospectively. Any post-CCRT maximum mouth openings (MMO) ≤ 35 mm were considered RIT. The GINI index was calculated using the formula: GINI = (CRP x Monocytes x Platelets x Neutrophils) ÷ (Albumin x Lymphocytes). We used receiver operating characteristic (ROC) curve analysis to examine the potential correlation between pretreatment GINI measures and post-CCRT RIT status. Logistic regression analysis examined the independence of the association between confounding factors and RIT rates. The study comprised 230 participants, and 52 (22.6%) received an RIT diagnosis. The optimal pre-CCRT GINI cutoff that dichotomizes RIT rates was determined to be 1,424 (area under the curve [AUC]: 76%; sensitivity: 75.0%; specificity: 71.7%; J-index: 0.463). RIT incidence was significantly higher in the GINI ≥ 1424 group than in its GINI < 1424 counterpart (43.3% vs. 9.3%; hazard ratio: 4.76; P < 0.001). Multivariate logistic regression analysis revealed that a pre-CCRT GINI ≥ 1424 was an independent predictor of increased RIT rates after definitive CCRT in this patient group (P < 0.001). In conclusion, the present results revealed that elevated pre-CCRT GINI measures (≥ 1424) can efficiently and independently predict elevated RIT rates in LA-NPC patients after CCRT.
4 August 2025 in European Journal of Breast Health
Regional nodal irradiation (RNI) is one of the main causes of breast cancer-related lymphedema (BCRL). However, studies on the relationship between the radiation dose to the axillary-lateral thoracic vessel juncture (ALTJ) region and BCRL have reported conflicting results. Based on these findings, we aimed to evaluate the clinical relevance of the dose to the ALTJ region in our patient cohort. Patients diagnosed with breast cancer and who were treated at Koç University Hospital between 2016 and 2022 and received RNI were included. BCRL was defined as a difference in arm circumference between the ipsilateral and contralateral limb >2.5 cm at any single encounter or ≥2 cm on ≥2 visits. ALTJ was retrospectively contoured, and doses were recorded as equivalent dose (α/β = 3). Of the 129 patients (median age 49 years) who met the inclusion criteria, 12 (9.3%) had lymphedema. Two-thirds of the patients (66.7%) were stage II, and one-third (33.3%) were stage III. The median follow-up was 22 months. The median (range) ALTJ Dmean dose was 18.11 (1.87-50) Gy, the median ALTJ Dmax was 44.53 (12.8-71.1) Gy, and the median ALTJ V35 was 38% (1-100%). No significant association was determined between ALTJ parameters and BCRL. There is insufficient data to define ALTJ as an OAR for decreasing BCRL risk. It is not appropriate to define dose and target based on ALTJ. Prospective studies with larger patient populations are needed to clarify the relationship between ALTJ and lymphedema.
Although concurrent chemoradiotherapy (CCRT) has improved outcomes in locally advanced head and neck cancer (LA-HNC), radiation-induced periodontitis (RIP) remains an under-recognized oral toxicity with significant consequences, including tooth loss and osteoradionecrosis. This study evaluates the utility of the novel CARWL score—a combined index of the C-reactive protein-to-albumin ratio (CAR) and significant weight loss (SWL)—for stratifying the risk of RIP in LA-HNC patients without baseline periodontitis undergoing CCRT. We conducted a retrospective analysis of 67 LA-HNC patients who underwent CCRT and received detailed oral examinations before and after treatment; none had periodontitis at the initiation of CCRT. Receiver operating characteristic (ROC) curve analysis identified an optimal pretreatment CAR cutoff of 3.07, with SWL defined as greater than 5% body weight loss in the preceding six months. Based on CAR (≥3.07 vs. <3.07) and SWL (present vs. absent), patients were categorized into three CARWL groups. The primary endpoint was the association between the baseline CARWL group and the rates of RIP following CCRT. RIP was diagnosed in 17 patients (25.4%) during follow-up, with incidences increasing progressively across CARWL-0, CARWL-1, and CARWL-2 groups (11.8% vs. 20.8% vs. 38.5%; p = 0.007). In multivariable Cox proportional-hazards analysis, a higher CARWL score emerged as an independent predictor of increased RIP risk (adjusted HR = 3.64; 95% CI 1.41–9.37; p = 0.007), and supplementary logistic regression sensitivity analysis corroborated these findings (adjusted OR = 3.58; 95% CI 1.35–9.45). These findings demonstrate that the pretreatment CARWL score serves as a straightforward and readily available biomarker that effectively stratifies the risk of radiation-induced periodontitis in LA-HNC patients treated with CCRT.
15 April 2025 in European Journal of Surgical Oncology